Review: Efficacy and Safety of Hybrid Therapy for Helicobacter pylori Infection: A Systematic Review and Meta-analysis

Helicobacter

Volumn 20, Issue 2, 2015, Pages 79-88

  Wang, Ben ^a   Wang, You Hua ^a   Lv, Zhi Fa ^a   Xiong, Hui Fang ^a   Wang, Hui ^a   Yang, Yang ^a   Xie, Yong ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Drug therapy; Eradication; H. pylori

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; ESOMEPRAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; TINIDAZOLE; ANTIINFECTIVE AGENT; BISMUTH; METRONIDAZOLE; PROTON PUMP INHIBITOR;

ANTIBIOTIC THERAPY; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; HYBRID THERAPY; INFORMATION RETRIEVAL; MEDICATION COMPLIANCE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADVERSE EFFECTS; DRUG COMBINATION; HELICOBACTER INFECTIONS; PROCEDURES; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

AMOXICILLIN; ANTI-INFECTIVE AGENTS; BISMUTH; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HUMANS; METRONIDAZOLE; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84924415790     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12180     Document Type: Review

References (44)

1. McColl KE. Clinical practice Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997;9:1-2.
3. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
4. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
5. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
6. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.e3; Discussion e12-3.
7. Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008;14:7361-70.
8. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.
9. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23-34.
10. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16:139-45.
11. O'Connor A, Molina-Infante J, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter 2013;18(Suppl 1):58-65.
12. Cetinkaya ZA, Sezikli M, Guzelbulut F, Cosgun S, Duzgun S, Kurdas OO. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin. Helicobacter 2010;15:143-7.
13. Romano MIM, Bermejo MF, Federico A, et al. 14-Day, high-dose acid suppression, non-bismuth quadruple therapies (hybrid vs. concomitant) for Helicobacter pylori infection: a randomized trial Javier. Gastroenterology 2013;144:S53.
14. Chang SN, Wu DC, Wu JY, Lai KH, Hsu PI. A prospective randomized trial of two 14-day sequential therapies for Helicobacter pylori eradication. J Gastroenterol Hepatol 2009;24:A20.
15. Wu JY, Hsu PI, Wu DC, Graham D. Optimal duration to maintain greater than 95% eradication rate in hybrid therapy for H. pylori. Gastroenterology 2012;142:S484.
16. Wu JY, Hsu PI, Wu DC, Graham DY, Wang WM. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter 2014;19:207-13.
17. Chitsaz E. Concomitant, sequential, and hybrid therapy for Helicobacter pylori: which one is the correct answer? Clin Res Hepatol Gastroenterol 2013;37:e125-6.
18. Graham DY, Gisbert JP. Helicobacter pylori: tailored therapy with novel sequential quadruple therapies. Nat Rev Gastroenterol Hepatol 2013;10:6-8.
19. Oh DH, Lee DH, Kang KK, Park YS, Shin CM, Kim N, Yoon H, Hwang J H. Efficacy of hybrid and sequential therapies as first-line treatment for H. pylori infection in Korea. J Gastroenterol Hepatol 2013;28:327.
20. Hsu P, Wu D, Wu J, Graham D. Search for a Grade A therapy for H. pylori eradication: 14-day sequential or sequential concomitant hybrid therapy. Helicobacter 2010;15:314.
21. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013;18:129-34.
22. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013;145:121-128.e1.
23. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014;63(Pt 5):748-52.
24. Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D'Ambrosio P, Castorani L, Bonfrate L, Vannella L, Hassan C, Portincasa P. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013;37:647-50.
25. Gisbert JP, Calvet X, Gomollon F, Mones J. Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference. Med Clin (Barc) 2005;125:301-16.
26. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, Sorrentino D, Gasbarrini G. "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007;39:782-9.
27. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.
28. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272-7.
29. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
30. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14.
31. Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 2013;18:274-9.
32. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002;16:1149-56.
33. Yoon H, Lee DH, Kim N, Park YS, Shin CM, Kang KK, Oh D H, Jang D K, Chung J W. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 2013;28:1801-9.
34. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-7.
35. Francavilla R, Lionetti E, Castellaneta S, Margiotta M, Piscitelli D, Lorenzo L, Cavallo L, Ierardi E. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. J Pediatr 2010;157:228-32.
36. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
37. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010;8:36-41.e31.
38. Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother 2013;14:211-23.
39. Graham DY, Rimbara E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol 2011;45:309-13.
40. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011;17:3971-5.
41. Riahizadeh S, Malekzadeh R, Agah S, et al. Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. Helicobacter 2010;15:497-504.
42. Kim SY, Lee SW, Hyun JJ, Jung SW, Koo JS, Yim HJ, Park JJ, Chun HJ, Choi JH. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J Clin Gastroenterol 2013;47:21-4.
43. Bang CS, Baik GH. Attempts to enhance the eradication rate of infection. World J Gastroenterol 2014;20:5252-62.
44. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002;19:67-70.